Life Technologies Corporation sequence-based system for HLA typing

Thursday, 21 February, 2013 | Supplied by: Life Technologies



Life Technologies Corporation has received US Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore HLA typing kits. The Applied Biosystems 3500 Dx/3500xL Dx CS2 Genetic Analyzers, Invitrogen SeCore HLA Sequencing Kits and uTYPE Dx HLA Sequence Analysis Software constitute the first 510(k)-cleared, sequence-based system for HLA typing in the United States.

Tissue typing is an essential component of determining compatibility between donors and patients for organ and bone marrow transplantation. HLA typing on the 3500 Dx offers labs an optimised, streamlined workflow said to have higher resolution than other molecular HLA typing technologies such as sequence-specific oligonucleotide (SSO) methods.

Online: www.invitrogen.com
Phone: 1800 331 627
Related Products

Fluidic Analytics Fluidity One-W for protein analysis

The Fluidity One-W instrument, from Fluidic Analytics, is able to assess on-target protein...

Integrated DNA Technologies oPools Oligo Pools

Integrated DNA Technologies (IDT) has launched oPools Oligo Pools — ready-to-use pools of...

Phase Genomics Hi-C proximity ligation kits

Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale...


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd